B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages

A new observational study of more than 8,000 prostate tumors shows that B7‑H3 (CD276) expression helps shape prognosis and could open new paths for targeted therapies. Researchers analyzed 8,157 prostate cancer samples with matched DNA and RNA data, stratifying them by tissue site, hormone‑sensitivity status, and self‑reported race, then examined how B7‑H3 levels related to overall survival and molecular features.

B7‑H3 expression was broadly maintained across different disease states, but its levels varied by tumor site, hormone scenario, and race. High B7‑H3 aligned with androgen receptor–related transcription factors such as HOXB13 and FOXA1 and with AR‑associated dysregulations including AR‑V7, SPOP alterations, and TMPRSS2:ERG fusions. It also correlated with other actionable surface antigens such as TROP2 and NECTIN‑4, which are already being explored as targets for antibody‑drug conjugates.

In contrast, high B7‑H3 showed only weak associations with regulators of lineage plasticity such as EZH2, SOX2, and ASCL1, as well as with neuroendocrine‑associated surface antigens like DLL3 and CEACAM5. This pattern suggests that B7‑H3 is more closely tied to AR‑driven biology than to full neuroendocrine transformation, which may help refine its role as a marker and target in treatment‑naïve or hormone‑sensitive disease.

When the team looked at overall survival, the direction of the B7‑H3 signal depended on clinical context. In primary tumors and hormone‑sensitive prostate cancer, high B7‑H3 portended worse survival, with hazard ratios around 1.3–1.35 and statistical significance below multiple‑testing thresholds. In metastatic tumors, the same high expression was associated with better overall survival, with a hazard ratio of about 0.82 and a clear p‑value advantage. This flip in prognostic meaning hints that B7‑H3 may mark different biological or microenvironmental states in early‑stage versus advanced disease.

In castration‑resistant and neuroendocrine prostate cancers, high versus low B7‑H3 did not yield a statistically significant difference in overall survival, but the study did detect racial differences in metastatic disease. Asian/Pacific Islander patients with metastatic prostate cancer showed the poorest survival among the groups analyzed independently from B7-H3 expression, with a hazard ratio of about 3.7, pointing to disparities that deserve further exploration in matched cohorts.

Because B7‑H3 expression remains stable across many disease settings, the findings support its continued evaluation as a target for therapies such as antibody‑drug conjugates, bispecific antibodies, or cell‑based approaches. The co‑occurrence of B7‑H3 with other surface antigens raises the possibility of dual‑targeting strategies that could broaden efficacy or delay resistance. For investigators and clinicians, this work strengthens the rationale to stratify patients by B7‑H3–related molecular features in trials and to consider tissue site and race when interpreting its prognostic signal.

Source.